Greatest decline in MME volume per capita seen among persons aged 46 to 55 years and in metropolitan counties
MONDAY, Dec. 27, 2021 (HealthDay News) — During the last decade, there has been a decline in total opioid morphine milligram equivalents (MME) per capita, according to a research letter published online Dec. 28 in the Annals of Internal Medicine.
Bradley D. Stein, M.D., Ph.D., from the RAND Corporation in Pittsburgh, and colleagues examined changes in the total number of opioid prescriptions filled at retail pharmacies by patient, prescriber, and county characteristics between 2008 through 2009 and 2017 through 2018.
The researchers found that from 2008-2009 to 2017-2018, there was a 21.2 percent decrease in total opioid MME volume per capita by prescriptions filled in retail pharmacies, from 951.4 to 749.3 MME. The greatest decline in MME volume per capita was among persons aged 46 to 55 years (664.6 MME; 33.7 percent decrease), while the greatest percentage decline was seen among persons aged 18 to 25 years (140.2; 66.6 percent). The greatest decline in per-capita MME volume was seen in metropolitan counties (219.8 MME; 22.6 percent) and in counties in the quartile with the highest fatal overdose rate (473.8 MME; 34.6 percent). Both within and across states, there was considerable variation observed. Across most specialties, there was a decrease in opioid MME volume per practicing clinician.
“These results suggest that the effects of clinician and policymaker efforts to reduce opioid prescribing may have differentially affected different populations, and future efforts to enhance clinically appropriate opioid prescribing may need to be more clinically nuanced and targeted for specific populations,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Withdrawal From Medetomidine Increasingly Seen in ICUs
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
Study Looks at Patient Experiences With Sedative Contaminating Fentanyl
Distinct Characteristics ID"d for Patients With Rheumatoid Conditions, Opioid Use Disorder
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus
Rheumatic Immune-Related AEs With Immune Checkpoint Inhibitors More Severe Than Previously Reported